dobutamine + terlipressin

Dobutamine + terlipressin is a combination of two intravenous drugs used in critical care settings, particularly for patients with septic shock or advanced liver disease complicated by hepatorenal syndrome. Dobutamine is a synthetic catecholamine and acts as a beta-1 adrenergic agonist, increasing cardiac contractility and output. Terlipressin is a synthetic vasopressin analogue that acts primarily as a vasoconstrictor via V1 receptors, leading to increased vascular tone and improved renal perfusion. The combination has been studied to counteract the reduction in cardiac output caused by terlipressin alone; dobutamine reverses the cardio-suppressive effects of terlipressin while maintaining hemodynamic stability and reducing norepinephrine requirements[1][2][3][9]. This regimen may be considered in select cases where both improved systemic perfusion (via dobutamine) and splanchnic/renal vasoconstriction (via terlipressin) are desired.